Who Still Needs Surgery? Defining the Modern Surgical Phenotype in Inflammatory Bowel Disease
The American Surgeon™ · 03.08.2026
DOI: 10.1177/00031348261474196 ↗Kurz gefasst
Fachartikel in der Zeitschrift The American Surgeon™, online erschienen am 03.08.2026. Verfasst von Taylor E Messick-Ngo und 7 weiteren Autor:innen. Beteiligte Einrichtung: General Surgery, Riverside Community Hospital, Riverside, CA, USA. Die Arbeit nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Inflammatory bowel disease (IBD), affecting over 2 million individuals in the United States, is associated with substantial morbidity, recurrent hospitalizations, and need for long-term immunosuppressive therapy. Although biologic therapies have been associated with declining operative rates in IBD, a clinically significant subset of patients continues to progress to surgery despite biologic exposure.
Methods
This retrospective cohort study evaluated surgical intervention rates among patients with Crohn’s disease (CD) and ulcerative colitis (UC) across two biologic treatment eras using the TriNetX Research Network, a multi-institutional database of de-identified electronic health records. Adult patients (ages 18-90) receiving biologic therapy were divided into two cohorts: 2004-2014 and 2014-2024. Surgical intervention following biologic initiation was used as a surrogate for treatment failure, and propensity score matching was performed to reduce confounding.
Results
After matching, 9822 patients remained in each cohort. Surgical intervention occurred in 8.4% of patients in the earlier cohort compared with 5.9% in the contemporary cohort, corresponding to a 29.8% relative reduction in operative intervention (RR 1.426, 95% CI 1.285-1.583; P < 0.001). Patients in the earlier cohort also demonstrated significantly higher risk of surgery within 1 year of biologic initiation. Within the contemporary cohort, CD patients continued to demonstrate higher operative risk compared with UC.
Discussion
Contemporary biologic therapy was associated with reduced operative intervention over time; however, persistent operative burden remains despite biologic exposure, particularly among patients with CD and nutritional compromise.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- General Surgery, Riverside Community Hospital, Riverside, CA, USA.
- Riverside School of Medicine, University of California, Riverside, CA, USA.
- Trauma and Acute Care Surgery, Riverside Community Hospital, Riverside, CA, USA.
- Colorectal Surgery, Riverside Community Hospital, Riverside, CA, USA.
ORCID-Profile: Jasmine Kazemi Gwizdala, Emily D Dubina
Zitieren
APA
Messick-Ngo, T. E., Boyer, K., Potalivo, S., Gwizdala, J. K., Scally, G., Dubina, E. D., Sheets, N., & Emdadi, A. (2026). Who Still Needs Surgery? Defining the Modern Surgical Phenotype in Inflammatory Bowel Disease. The American Surgeon™. https://doi.org/10.1177/00031348261474196
Vancouver
Messick-Ngo TE, Boyer K, Potalivo S, Gwizdala JK, Scally G, Dubina ED, et al. Who Still Needs Surgery? Defining the Modern Surgical Phenotype in Inflammatory Bowel Disease. The American Surgeon™. 2026. doi:10.1177/00031348261474196
BibTeX
@article{MessickNgo2026,
author = {Messick-Ngo, Taylor E and Boyer, Kaitlin and Potalivo, Sophia and Gwizdala, Jasmine Kazemi and Scally, Gabriel and Dubina, Emily D and Sheets, Nicholas and Emdadi, Aras},
title = {Who Still Needs Surgery? Defining the Modern Surgical Phenotype in Inflammatory Bowel Disease},
journal = {The American Surgeon™},
year = {2026},
doi = {10.1177/00031348261474196}
}
EUVIMED